# Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

> **NCT01937442** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide Celgene™

## Key facts

- **NCT ID:** NCT01937442
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-07
- **Primary completion:** 2015-09-23
- **Final completion:** 2015-09-23
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937442, "Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01937442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*